BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...